Is Zoetis Inc. (ZTS) A Good Stock To Buy Now?

Is ZTS a bully banal to buy? We came crossed a bullish thesis on Zoetis Inc. connected Quality At A Fair Price’s Substack. In this article, we volition summarize the bulls’ thesis connected ZTS. Zoetis Inc.'s stock was trading astatine $117.52 arsenic of April 22^nd. ZTS’s trailing and guardant P/E were 19.52 and 16.75 respectively according to Yahoo Finance.

Lucky Business/Shutterstock.com

Zoetis Inc. (ZTS) is positioned arsenic the planetary person successful carnal health, specializing successful medicines, vaccines, diagnostics, and technologies that enactment some companion and livestock carnal care, and it continues to payment from structurally durable request trends pursuing its spin-off from Pfizer. The Dividend Yield Theory model suggests that contempt its antiaircraft concern exemplary and accordant net quality, the banal is presently mispriced, trading astatine $131.94 versus an implied just worth of $229, indicating a important ~42% discount and pointing to meaningful upside imaginable if valuation normalizes.

Read More: 15 AI Stocks That Are Quietly Making Investors Rich

Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential

The company’s dividend illustration reinforces this prime narrative, with a guardant output of 1.63% compared to a 5-year mean output of conscionable 0.93%, suggesting the existent introduction constituent is historically much charismatic contempt a humble caller ~6% dividend increase. Importantly, Zoetis maintains a beardown way grounds of dividend growth, with 3-, 5-, and 10-year dividend maturation rates consistently supra 12%, highlighting durable currency travel procreation and disciplined superior allocation.

While humanities CAGR trends amusement periods of compression, the guardant outlook shifts the communicative materially, with estimated EPS maturation of 8.58% and a projected aboriginal CAGR of 17.53%, supported by valuation normalization via a 7.31% re-rating factor.

Even though caller show has reflected volatility, the semipermanent structural drivers—expanding favored ownership, premiumization of carnal healthcare, and recurring pharmaceutical demand—remain intact and supportive of sustained growth. Overall, Zoetis stands retired arsenic a high-quality compounder trading beneath intrinsic value, with dividend stability, beardown maturation visibility, and a compelling rerating accidental that collectively make an charismatic risk-reward setup for semipermanent investors.

Previously, we covered a bullish thesis connected Zoetis Inc. (ZTS) by Best Anchor Stocks successful December 2024, which highlighted the company’s accelerating maturation driven by its OA symptom MAB franchise, beardown beat-beat-raise quarters, and expanding marketplace creation. ZTS's banal terms has depreciated by astir 28.65% since our coverage. Quality At A Fair Price shares a akin presumption but emphasizes valuation mispricing and dividend yield-based upside potential.